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Background
- SGLT2 inhibitors have been shown to have 
a significant benefit for patients with DM2 or 
CAD (DAPA-HF, Emperor-reduced)
- The usage of these medications are low 
compared to other Goal Directed Medical 
Therapy.
- There are multiple contributing factors as to 
why these medications are underutilized
Aims For Improvement
Our aim is to assess barriers against 
prescription of SGLT2-i at the time of 
discharge from TJUH and to increase 
utilization after placement on formulary.
Intervention
- Expanding SGLT2-i availability in the 
inpatient setting by adding them on 
formulary.
- Survey attending level physicians 0n their 
SGLT2 inhibitor prescribing practices.
Measurements/ Results
Lessons Learned
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• Add SGLT2-i to 
inpatient formulary
• Compare pre-formulary 
and post-formulary 
utilization
• Develop resources to 
promote best practice 






Prescribing (1 to 5) 
(SDEV)
Most Common Factor 
Preventing Initiating as Inpatient
Hospital 
Medicine (4)




4.86 (0.38) Preference for outpatient initiation, lack of 
availability inpatient
Cardiology (17) 3.29 (1.36) Cost of medication
Did you meet your aim for improvement?
We determined barriers to inpatient prescription 
and saw an increase after the medications was added 
on formulary. However, the increase in prescriptions 
was not as dramatic as expected.
If not, why not? What will you do or what would 
you recommend the next team to in order to 
improve on your efforts?
Despite removing the barrier of non-formulary 
status for SGLT2-is, there remains a large gap 
between patients who have an indication to begin 
therapy and those who were appropriately 
prescribed it while at TJUH.
If yes, what will your next goal for improvement be 
and how will you reach it?
The next goal is to increase the number of providers 
comfortable with prescribing SGLT2-i during an 
inpatient stay, in an effort to increase appropriate 
prescriptions of SGLT2-i in the inpatient setting.
To do this, we can provide EMR guidelines and 
education modules on when to initiate therapy and 
to clarify contraindications on inpatient initiation.
What did your team learn about the improvement 
process?
In addition to removing barriers for quality gaps, it 
is necessary to actively facilitate changes practicing 
trends regarding evolving clinical updates to 
optimize patient care.




12 new Rx 
per 909 
eligible 
patients
